Project Grant R34HL180904
- The National Heart, Lung, and Blood Institute awarded The Washington University $764,681 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, to conduct research into a multipotent fibroblast population and platelet-derived growth factor receptor beta–dependent immuno-fibrotic responses in heart failure. The research addresses cardiac fibrosis and left ventricular dysfunction in heart failure by investigating a novel population of stem cell antigen-1–expressing,...
- The National Heart, Lung, and Blood Institute awarded the University of Pennsylvania $685,212 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop policy-relevant evidence on the scope and effects of prior authorization (PA) for cardiovascular care. The project quantifies patient exposure to PA for cardiovascular services from 2016 through 2024, identifying which patient groups experience PA barriers and measuring how PA affects service use, care...
- The National Heart, Lung, and Blood Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Washington University $768,128 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to mechanistically evaluate the role of oscillatory shear stress in deep vein thrombosis prevention. The recipient will conduct in vitro, in vivo, and human model studies to determine whether restoration of oscillatory shear stress in veins...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The Washington University $635,247 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of resolution-phase neutrophils in acute respiratory distress syndrome (ARDS) recovery. The project tests the hypothesis that neutrophils activate counter-regulatory mechanisms, including expression of 15-lipoxygenase (15-LO), in lung tissue following acute injury to...
- The National Heart, Lung, and Blood Institute awarded The University of Chicago $642,477 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a targeted quality improvement trial improving post-discharge venous thromboembolism (VTE) chemoprophylaxis following abdominal and pelvic cancer surgery. The trial addresses the gap between clinical evidence and practice adoption. Randomized trials have demonstrated that chemoprophylaxis extending beyond...
- The National Heart, Lung, and Blood Institute awarded The Washington University $459,175 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance high-density diffuse optical tomography (HD-DOT) methods for perioperative neuromonitoring in children with congenital heart disease. The project develops HD-DOT technology to evaluate brain health through bedside neuroimaging of functional connectivity and cerebral oxygenation in perioperative settings. The...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Washington University $761,782 under the Cardiovascular Diseases Research program (CFDA 93.837) beginning September 1, 2025, with completion targeted for July 31, 2029. This project grant funds basic and translational research investigating the loss of cilia maintenance mechanisms in acquired and genetic lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The...
- The National Heart, Lung, and Blood Institute awarded The Washington University $803,772 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the mitochondrial calcium uniporter in platelet function and thrombosis. The research addresses ischemic stroke prevention through basic and translational science. Approximately 700,000 people in the United States experience ischemic stroke annually, and current acute treatments restrict...
- The National Heart, Lung, and Blood Institute awarded The Washington University $1.902 million on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and correct immune-epithelial pathways underlying chronic muco-obstructive lung disease triggered by viral infection, allergen, smoke, or pollution exposure. The research identifies and characterizes a distinct subset of basal epithelial stem cells (basal-ESCs) that drive muco-obstructive disease phenotypes...
- The National Heart, Lung, and Blood Institute awarded the University of Massachusetts Medical School $858,456 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Assistance Listing R01HL184047) to develop and test an interoperable shared decision-making tool integrated into electronic health records for stroke prevention in atrial fibrillation patients. The project, titled DECIDE-AF, addresses suboptimal anticoagulation initiation and persistence among AF...
The National Heart, Lung, and Blood Institute awarded The Washington University $272,125 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to refine and pilot-test the PACE (Process for Adopting Clinical Evidence) tool, a digital implementation science platform designed to help hospital units identify and substitute low-value clinical practices with evidence-based alternatives. The project targets unnecessary procedures that expose patients to avoidable risk—including routine chest X-rays, prolonged urinary catheter use, and other low-value practices—that waste over $345 billion annually. The recipient's team has demonstrated 50% reductions in unnecessary emergency department chest X-rays and 80% reductions in indwelling urinary catheters in ICU settings through targeted substitution strategies. This R34 award funds feasibility testing to prepare for a larger multi-site R01 application. Work in Aim 1 refines the PACE tool for usability and real-world deployment through human-centered design workshops across two health systems (one academic, one community). Clinicians, nurses, and educators from four clinical units—two emergency departments and two ICUs—will test and improve the tool's interface and workflow. Aim 2 pilot-tests feasibility and acceptability through a randomized comparison of PACE-guided versus standard implementation across four clinical units. Performance occurs in St. Louis, Missouri. The award period runs from September 1, 2026, through June 30, 2029. This is a Project Grant assistance type.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $272.1k | 8/28/26 |